CoChat

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors

Open access
Romero-Calvo, Isabel, Weber, Christopher R., Ray, Mohana, Brown, Miguel, Kirby, Kori, Nandi, Rajib K., Long, Tiha M., Sparrow, Samantha M., Ugolkov, Andrey, Qiang, Wenan, Zhang, Yilin, Brunetti, Tonya, Kindler, Hedy, Segal, Jeremy P., Rzhetsky, Andrey, Mazar, Andrew P., Buschmann, Mary M., Weichselbaum, Ralph, Roggin, Kevin, White, Kevin P. · 2019 · Molecular Cancer Research

Published version of a preprint

Cited by 119

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the tumor of origin remain important unanswered questions limiting their utility. To address this gap in knowledge, primary tumor- and patient-derived xenograft (PDX)-derived organoids, and 2D cultures for in-depth genomic and histopathologic comparisons with the primary tumor were created. Histopathologic features and PDAC representative protein markers (e.g., claudin 4 and CA19-9) showed strong concordance. DNA- and RNA-sequencing (RNAseq) of single organoids revealed patient-specific genomic and transcriptomic consistency. Single-cell RNAseq demonstrated that organoids are primarily a clonal population. In drug response assays, organoids displayed patient-specific sensitivities. In addition, the in vivo PDX response to FOLFIRINOX and gemcitabine/abraxane treatments were examined, which was recapitulated in vitro with organoids. This study has demonstrated that organoids are potentially invaluable for precision medicine as well as preclinical drug treatment studies because they maintain distinct patient phenotypes and respond differently to drug combinations and dosage. Implications: The patient-specific molecular and histopathologic fidelity of organoids indicate that they can be used to understand the etiology of the patient's tumor and the differential response to therapies and suggests utility for predicting drug responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-18-0531

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 37

  1. Lee, 2006, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, Cancer Cell, 9, 391, 10.1016/j.ccr.2006.03.030 · DOI · Paper page
  2. van Staveren, 2009, Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells?, Biochim Biophys Acta, 1795, 92
  3. Bardeesy, 2006, Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse, Proc Natl Acad Sci U S A, 103, 5947, 10.1073/pnas.0601273103 · DOI · Paper page
  4. Rubio-Viqueira, 2006, An in vivo platform for translational drug development in pancreatic cancer, Clin Cancer Res, 12, 4652, 10.1158/1078-0432.CCR-06-0113 · DOI · Paper page
  5. Willey, 2015, Patient-derived xenografts as a model system for radiation research, Semin Radiat Oncol, 25, 273, 10.1016/j.semradonc.2015.05.008 · DOI
  6. Drost, 2016, Organoid culture systems for prostate epithelial and cancer tissue, Nat Protoc, 11, 347, 10.1038/nprot.2016.006 · DOI · Paper page
  7. Jarde, 2016, Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone responsive mammary organoids, Nat Commun, 7, 13207, 10.1038/ncomms13207 · DOI · Paper page
  8. Moreira, 2018, Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer, Cell Mol Gastroenterol Hepatol, 5, 289, 10.1016/j.jcmgh.2017.12.004 · DOI
  9. Kleinman, 2003, Role of the extracellular matrix in morphogenesis, Curr Opin Biotechnol, 14, 526, 10.1016/j.copbio.2003.08.002 · DOI · Paper page
  10. Griffith, 2006, Capturing complex 3D tissue physiology in vitro, Nat Rev Mol Cell Biol, 7, 211, 10.1038/nrm1858 · DOI · Paper page
  11. Kadri, 2017, Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays, J Mol Diagn, 19, 43, 10.1016/j.jmoldx.2016.07.012 · DOI
  12. Martin, 2011, Cutadapt removes adapter sequences from high-throughput sequencing reads, 10
  13. Quinlan, 2010, BEDTools: a flexible suite of utilities for comparing genomic features, Bioinformatics, 26, 841, 10.1093/bioinformatics/btq033 · DOI · Paper page
  14. Cibulskis, 2013, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat Biotechnol, 31, 213, 10.1038/nbt.2514 · DOI · Paper page
  15. Fang, 2016, Indel variant analysis of short-read sequencing data with Scalpel, Nat Protoc, 11, 2529, 10.1038/nprot.2016.150 · DOI
  16. McLaren, 2010, Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor, Bioinformatics, 26, 2069, 10.1093/bioinformatics/btq330 · DOI · Paper page
  17. Morgulis, 2006, A fast and symmetric DUST implementation to mask low-complexity DNA sequences, J Comput Biol, 13, 1028, 10.1089/cmb.2006.13.1028 · DOI · Paper page
  18. Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
  19. Teh, 2006, Hierarchical Dirichlet processes, 1566
  20. Matros, 2006, Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival, Cancer, 106, 693, 10.1002/cncr.21609 · DOI
  21. Chu, 2000, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases, Mod Pathol, 13, 962, 10.1038/modpathol.3880175 · DOI · Paper page
  22. Yemelyanova, 2011, Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis, Mod Pathol, 24, 1248, 10.1038/modpathol.2011.85 · DOI · Paper page
  23. Boogerd, 2017, Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic and rectal cancer tissue, Biomarkers Cancer, 9, 1179299x17710016, 10.1177/1179299X17710016 · doi:10.1177/1179299x17710016
  24. Zapata, 2007, Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role, CytoJournal, 4, 13, 10.1186/1742-6413-4-13 · DOI
  25. Schmuck, 2016, Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity, Cancer Med, 5, 88, 10.1002/cam4.566 · DOI
  26. Gnoni, 2013, Carcinogenesis of pancreatic adenocarcinoma: precursor lesions, Int J Mol Sci, 14, 19731, 10.3390/ijms141019731 · DOI
  27. Ando, 2015, Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer, Cancer Med, 4, 75, 10.1002/cam4.346 · DOI
  28. Neesse, 2013, Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions, Gut, 62, 1034, 10.1136/gutjnl-2012-302577 · DOI · Paper page
  29. Michl, 2001, Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin, Gastroenterology, 121, 678, 10.1053/gast.2001.27124 · DOI · Paper page
  30. Partyka, 2012, Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation, Proteomics, 12, 2212, 10.1002/pmic.201100676 · DOI · Paper page
  31. Ichihara, 1988, Immunohistochemical localization of CA 19-9 and CEA in pancreatic carcinoma and associated diseases, Cancer, 61, 324, 10.1002/1097-0142(19880115)61:2<324::AID-CNCR2820610223>3.0.CO;2-Q · doi:10.1002/1097-0142(19880115)61:2<324::aid-cncr2820610223>3.0.co;2-q
  32. Allum, 1986, Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry, J Clin Pathol, 39, 610, 10.1136/jcp.39.6.610 · doi:10.1136/jcp.39.6.610
  33. Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 · DOI · Paper page
  34. Hori, 2013, Prominin-1 (CD133) reveals new faces of pancreatic progenitor cells and cancer stem cells: current knowledge and therapeutic perspectives, Adv Exp Med Biol, 777, 185, 10.1007/978-1-4614-5894-4_12 · DOI
  35. Busser, 2011, The multiple roles of amphiregulin in human cancer, Biochim Biophys Acta, 1816, 119
  36. Wang, 2016, Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma, Diagn Pathol, 11, 60, 10.1186/s13000-016-0512-4 · DOI
  37. Funatomi, 1997, Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy, Int J Cancer, 72, 512, 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C · doi:10.1002/(sici)1097-0215(19970729)72:3<512::aid-ijc21>3.0.co;2-c

Cited by

See all 119

Metadata

Authors
Romero-Calvo, I., Weber, C. R., Ray, M., Brown, M., Kirby, K., Nandi, R. K., Long, T. M., Sparrow, S. M., Ugolkov, A., Qiang, W., Zhang, Y., Brunetti, T., Kindler, H., Segal, J. P., Rzhetsky, A., Mazar, A. P., Buschmann, M. M., Weichselbaum, R., Roggin, K., & White, K. P.
Venue
Molecular Cancer Research
Published
2019-01-01
Volume
17
Issue
1
Pages
70-83
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2889176487
Cited by
119
References
18
FWCI
3.71
Type
journal article
Language
en
Open access
green
Funders
  • NIH (U10CA180836)
  • NCI (U54CA193419)
  • CCSG (P30 CA060553)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-18-0531
The paper
Romero-Calvo, I., Weber, C. R., Ray, M., Brown, M., Kirby, K., Nandi, R. K., Long, T. M., Sparrow, S. M., Ugolkov, A., Qiang, W., Zhang, Y., Brunetti, T., Kindler, H., Segal, J. P., Rzhetsky, A., Mazar, A. P., Buschmann, M. M., Weichselbaum, R., Roggin, K., & White, K. P. (2019). Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-18-0531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.